Categories: NewsPharmaceutical

Ventyx Biosciences to Host R&D Event on January 26, 2023

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

ENCINITAS, Calif., Jan. 05, 2023 (GLOBE NEWSWIRE) — Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced that it will host an R&D event on Thursday, January 26, 2023 in New York City from 9-11:30 a.m. ET. The event will highlight key aspects of Ventyx’s clinical-stage and discovery programs.

Participating in the presentations and discussions will be members of the Ventyx Executive Team and Clinical Advisors, including:

  • Raju Mohan, PhD, Founder, Chief Executive Officer and Director
  • William Sandborn, MD, President and Chief Medical Officer
  • John Nuss, PhD, Chief Scientific Officer
  • James Krueger, MD, PhD, Director of the Milstein Medical Research Program and D. Martin Carter Professor in Clinical Investigation at Rockefeller University in New York

A live webcast of the event will be available in the “Investors” section of the Ventyx website at www.ventyxbio.com. A webcast replay will also be available on this website shortly after conclusion of the event.

About Ventyx Biosciences

Ventyx is a clinical-stage biopharmaceutical company focused on developing innovative oral medicines for patients living with autoimmune and inflammatory disorders. We believe our ability to efficiently discover and develop differentiated drug candidates will allow us to address important unmet medical need with novel oral therapies that can shift immunology markets from injectable to oral drugs. Our current pipeline includes three internally discovered clinical programs targeting TYK2, S1P1R and NLRP3, positioning us to become a leader in the development of oral immunology therapies. Ventyx is headquartered in Encinitas, California. For more information about Ventyx, please visit www.ventyxbio.com.

Investor Relations Contact
Patti Bank
Managing Director
ICR Westwicke
(415) 513-1284
IR@ventyxbio.com

Staff

Recent Posts

Adia Nutrition Launches Second National Television Campaign Showcasing U.S.-Based Regenerative Stem Cell Therapies

Winter Park, Florida--(Newsfile Corp. - August 21, 2025) - Adia Nutrition Inc. (OTCQB: ADIA), a…

2 hours ago

Apollo Biowellness, Inc., Launches New Product Brand

radeditorformatted_6North Bergen, New Jersey--(Newsfile Corp. - August 21, 2025) - Apollo Biowellness, Inc. (OTC Pink:…

2 hours ago

NaphCare Launches Specialized EHR Solution for Georgia Department of Corrections

NaphCare and the Georgia Department of Corrections successfully implemented TechCare 5.0 EHR to serve incarcerated…

2 hours ago

NaphCare Launches Specialized EHR Solution for Georgia Department of Corrections

NaphCare and the Georgia Department of Corrections successfully implemented TechCare 5.0 EHR to serve incarcerated…

2 hours ago

Nalu Advances Wearable Neurostimulation with New, 39% Smaller Therapy Disc

CARLSBAD, Calif.--(BUSINESS WIRE)--Nalu Medical Inc., announced the release of a next-generation Therapy Disc—a significantly smaller,…

2 hours ago